[1]郑妮冰 陈 斌 彭丽云.PCSK9基因rs662145位点多态性与冠状动脉粥样硬化性心脏病血脂的关系[J].福建医药杂志,2020,42(04):1-5.
　ZHENG Nibing,CHEN Bin,PENG Liyun..Relationship between rs662145 polymorphism of PCSK9 gene and blood lipid in patients with coronary atherosclerotic heart disease[J].FUJIAN MEDICAL JOURNAL,2020,42(04):1-5.
点击复制

PCSK9基因rs662145位点多态性与冠状动脉粥样硬化性心脏病血脂的关系()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
42
期数:
2020年04期
页码:
1-5
栏目:
临床研究
出版日期:
2020-08-20

文章信息/Info

Title:
Relationship between rs662145 polymorphism of PCSK9 gene and blood lipid in patients with coronary atherosclerotic heart disease
文章编号:
1002-2600(2020)04-0001-05
作者:
郑妮冰 陈 斌 彭丽云
福建省立医院心内一科(福州 350001)
Author(s):
ZHENG Nibing; CHEN Bin; PENG Liyun.
Department of Cardiology,Fujian Provincial Hosptial,Fuzhou,Fujian 350001,China
关键词:
PCSK9基因;  rs662145位点;  冠心病;  脂代谢;  他汀
Keywords:
PCSK gene;  rs662145;  coronary heart disease;  lipid profiles;  statins
分类号:
R541.4
文献标志码:
B
摘要:
目的 探讨PCSK9基因rs662145位点多态性与冠状动脉粥样硬化性心脏病(coronary atherosclerotic heart disease,CHD)的关系,并观察他汀在PCSK基因rs662145位点不同基因型中调脂效果的差异。方法 选取行CAG检查的福建汉族患者261例,根据CAG结果分为CHD组和对照组,收集患者的基本资料并留取空腹血标本,测定TG、TC、LDL-C等血脂指标,采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术检测PCSK9基因rs662145位点多态性,并在完成随访的57例患者复测相应血脂指标。结果 CHD组rs662145位点C等位基因频率为20.59%,高于对照组的10.53%(χ2=6.011,P=0.019); CC、CT、TT基因型频率在两组间分布差异也有统计学意义(χ2=9.418,P=0.007); 含C等位基因CHD组患者TC及LDL-C水平更高(CC>CT>TT,P<0.05),但HDL-C较低(CC<0.05)。chd组患者血浆tc、hdl-c、ldl-c、apoa水平在cc、ct、tt基因型亚组间的差异有统计学意义(p><0.05),对照组血脂水平在各基因型亚组间的差异无统计学意义(p>0.05)。CHD患者经过他汀治疗后,血浆TG、TC及LDL-C水平均较前降低,HDL-C水平较前升高(P<0.05),但CC、CT、TT各基因型患者经他汀治疗前后血脂变化值差异无统计学意义(P>0.05)。结论 PCSK9基因rs662145位点多态性与福建汉族冠心病人群血脂异常有关,rs662145位点C等位基因可能是冠心病高风险突变位点。/html>
Abstract:
Objective To explore the relationship between rs662145 polymorphism of PCSK9 gene and blood lipid in patients with coronary atherosclerotic heart disease,and to compare the efficacy of statins in various PCSK9 rs662145 genotypes in patients with coronary atheroscleroticheart disease.Methods A total of 261 patients undergoing coronary angiography were divided into CHD group(n=204)and control group(n=57).Basic information,fasting glucose,total triglyceride(TG), total cholesterol(TC)and low density lipoprotein cholesterol(LDL-C)and other lipid profiles were tested immediately after admission.Genotyping of PCSK9 polymorphisms was performed using polymerase chain reaction-restriction fragment length polymorphism(PCR-RFLP)method.Lipid profile was redetermined in patients who had accepted statins for three months and completed the follow-up.Results The frequency of C allele was 20.59% in CHD group,which was higher than 10.53% in the control group(χ2=6.011,P=0.019).The distribution of PCSK9 rs662145 genotype(CC,CT,TT)among two groups showed statistically significant difference(χ2=9.418,P=0.007).Patients with C allele in CHD group had higher levels of TC and LDL-C but lower HDL-C levels(P<0.05).TC,HDL-C,LDL-C and ApoA levels also demonstrated statistically significant difference between three genotypes(CC,CT and TT)in the CHD group(P<0.05),meanwhile no difference was seen in the lipid profiles of the control group among three genotypes.TG,TC and LDL-C levels decreased with the elevation of HDL-C after three months treatment with statins in CHD group(P<0.05).No significant differences were observed in the variation of lipid profile after treatment with statins among three genotypes(CC,CT,TT)(P>0.05).Conclusion PCSK9 gene rs662145 polymorphism was associated with lipid levels in CHD patients among Fujian Han population.C allele may increase the risk of the onset of coronary heart disease.

参考文献/References:

[1] 胡盛寿,高润霖,刘力生,等.《中国心血管病报告2018》概要[J].中国循环杂志,2019,34(3):209-220.
[2] Ference Brian A,Ginsberg Henry N,Graham Ian,et al.Low-density lipoproteins cause atherosclerotic cardiovascular disease.1.Evidence from genetic, epidemiologic, and clinical studies.A consensus statement from the European Atherosclerosis Society Consensus Panel[J].Eur Heart J,2017,38(32):2459-2472.
[3] Pott J,Schlegel V,Teren A,et al.Genetic Regulation of PCSK9(Proprotein Convertase Subtilisin/Kexin Type 9)Plasma Levels and Its Impact on Atherosclerotic Vascular Disease Phenotypes[J]. Circulation Genomic & Precision Medicine,2018,11(5):e001992.
[4] Abifadel M,Varret M,Rabès J P,et al.Mutations in PCSK9 cause autosomal dominant hypercholesterolemia[J]. Nature Genetics,2003,34(2):154-156.
[5] Qiu C F,Zeng P Y,Li X H,et al.What is the impact of PCSK9rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk:a meta-analysis[J]. Lipids in Health and Disease,2017,16(1):111.
[6] Chuan J L,Qian Z X, Zhang Y,et al.The association of the PCSK9 rs562556 polymorphism with serum lipids level:A meta-analysis[J]. Lipids in health and disease,2019,18(1):105.
[7] Shibata N,Ohnuma T,Higashi S, et al.No genetic association between PCSK9 polymorphisms and Alzheimers disease and plasma cholesterol level in Japanese patients[J]. Psychiatric genetics,2005,15(4):239.
[8] 赵婷婷.PCSK9、LDLR基因多态性与生活行为因素对高脂血症影响的研究[D].新疆:石河子大学,2014.
[9] Zheng Li,Tianyu Zhao,Xiaohua Tan, et al.Polymorphisms in PCSK9, LDLR, BCMO1, SLC12A3,and KCNJ1 are Associated with Serum Lipid Profile in Chinese Han Population[J]. Int J Environ Res Public Health,2019,16(17):3207.
[10] 杨林承,祖凌云,高炜.PCSK9基因突变与冠心病[J].中国介入心脏病学杂志,2018,26(8):457-461.
[11] Feng Q,Wei W Q,Chung C P,et al.The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy[J]. Pharmacogenomics Journal,2017,17(2):204-208.
[12] 张楠,高静,刘寅,等.PCSK9基因E670G位点多态性与冠状动脉粥样硬化性心脏病罹病风险及脂代谢的相关性研究[J]. 中华医学遗传学杂志,2017,34(5):749-754.
[13] Wanmasae S,Sirintronsophon W,Porntadavity S,et al.The effect of APOE,CETP,and PCSK9 polymorphisms on simvastatin response in Thai hypercholesterolemic patients[J]. Cardiovascular Therapeutics,2017,35(6):doi: 10.1111/1755-5922.12302.

备注/Memo

备注/Memo:
基金项目:福建省卫生健康科研人才培养项目医学创新课题(2019-CXB-2)
更新日期/Last Update: 2020-08-20